CLINICAL TRIALS PROFILE FOR AGGRENOX

505(b)(2) Clinical Trials for AGGRENOX

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Formulation	NCT02273531 ↗	Bioequivalence of a New Asasantin Formulation Extended Release (ER) Compared to the Commercially Available Asasantin Formulation (Aggrenox®; Extended Release) in Healthy Male and Female Volunteers	Completed	Boehringer Ingelheim	Phase 1	2004-01-01	Study to establish the bioequivalence of a new formulation of Asasantin ER compared to the present commercially available Asasantin ER formulation (Aggrenox®)

All Clinical Trials for AGGRENOX

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00067119 ↗	Aggrenox Prevention of Access Stenosis	Completed	Baystate Medical Center	Phase 3	2003-01-01	The objective of the study is to determine whether Aggrenox (Boehringer-Ingelheim) prolongs primary unassisted patency in newly created arteriovenous grafts. This record previously included information for both the GRAFT and FISTULA trials.
NCT00067119 ↗	Aggrenox Prevention of Access Stenosis	Completed	Boston University	Phase 3	2003-01-01	The objective of the study is to determine whether Aggrenox (Boehringer-Ingelheim) prolongs primary unassisted patency in newly created arteriovenous grafts. This record previously included information for both the GRAFT and FISTULA trials.
NCT00067119 ↗	Aggrenox Prevention of Access Stenosis	Completed	CAMC Health System	Phase 3	2003-01-01	The objective of the study is to determine whether Aggrenox (Boehringer-Ingelheim) prolongs primary unassisted patency in newly created arteriovenous grafts. This record previously included information for both the GRAFT and FISTULA trials.
NCT00067119 ↗	Aggrenox Prevention of Access Stenosis	Completed	Duke University	Phase 3	2003-01-01	The objective of the study is to determine whether Aggrenox (Boehringer-Ingelheim) prolongs primary unassisted patency in newly created arteriovenous grafts. This record previously included information for both the GRAFT and FISTULA trials.
NCT00067119 ↗	Aggrenox Prevention of Access Stenosis	Completed	Emory University	Phase 3	2003-01-01	The objective of the study is to determine whether Aggrenox (Boehringer-Ingelheim) prolongs primary unassisted patency in newly created arteriovenous grafts. This record previously included information for both the GRAFT and FISTULA trials.
NCT00067119 ↗	Aggrenox Prevention of Access Stenosis	Completed	Maine Medical Center	Phase 3	2003-01-01	The objective of the study is to determine whether Aggrenox (Boehringer-Ingelheim) prolongs primary unassisted patency in newly created arteriovenous grafts. This record previously included information for both the GRAFT and FISTULA trials.

Clinical Trial Conditions for AGGRENOX

Condition Name

Condition Name for AGGRENOX
Intervention	Trials
Healthy	6
Cerebrovascular Accident	3
Stroke	3
Cardiovascular Disease	1

Condition MeSH

Condition MeSH for AGGRENOX
Intervention	Trials
Stroke	5
Ischemic Attack, Transient	1
Foramen Ovale, Patent	1
COVID-19	1

Clinical Trial Locations for AGGRENOX

Trials by Country

Trials by Country for AGGRENOX
Location	Trials
United States	56
Canada	9
Australia	4
Denmark	2
Japan	2

Trials by US State

Trials by US State for AGGRENOX
Location	Trials
Tennessee	3
New Jersey	2
Arizona	2
Texas	2
North Carolina	2

Clinical Trial Progress for AGGRENOX

Clinical Trial Phase

Clinical Trial Phase for AGGRENOX
Clinical Trial Phase	Trials
Phase 4	3
Phase 3	4
Phase 1	6

Clinical Trial Status

Clinical Trial Status for AGGRENOX
Clinical Trial Phase	Trials
Completed	14
Recruiting	1
Terminated	1

Clinical Trial Sponsors for AGGRENOX

Sponsor Name

Sponsor Name for AGGRENOX
Sponsor	Trials
Boehringer Ingelheim	11
Vanderbilt University	2
Vanderbilt University Medical Center	2

Sponsor Type

Sponsor Type for AGGRENOX
Sponsor	Trials
Other	23
Industry	14
NIH	1